Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads In AML

AML for November/December 2017

Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al

Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al

Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; S├ębert, Komrokji et al

Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al

Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al

More must reads

AML for September/October 2017

Cochrane on Value of TPO Mimetics for MDS, Cochrane; 2017 Sep 29; Dodillet, Kreuzer, et al

Allo-HSCT for Mixed Phenotype Acute Leukemia, Haematologica; ePub 2017 Sep 29; Munker, et al

CD34+ Cell-Selected Allo-HSCT Long-Term Outcomes, Biol Blood Marrow Transplant; ePub 2017 Oct 9; Cho, et al

Predicting Poor Prognosis After Induction Chemo, Leuk Res; ePub 2017 Sep 26; Ahmed, et al

CBF-AML + These Gene Defects = Poor Outcomes , Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 25; Kahn, et al

More must reads